<DOC>
	<DOCNO>NCT02162784</DOCNO>
	<brief_summary>The objective study evaluate dose response SYN006 HFA MDI , combination drug product budesonide procaterol hydrochloride , asthma patient . Patients mild moderate asthma recruit . There two study medication administer study . The investigational medication SYN006 ( Budesonide/Procaterol hydrochloride , 180 mcg/10 mcg per inhalation ) active comparative medication Ventolin ( Salbutamol sulfate 100 mcg per inhalation ) . The study medication administer oral inhalation supervision investigator qualify staff .</brief_summary>
	<brief_title>Efficacy Study SYN006 HFA MDI Asthma Patients</brief_title>
	<detailed_description>Three treatment administer patient : - A . Two inhalation Ventolin 100 mcg , - B . One inhalation SYN006 180/10 mcg , - C. Two inhalation SYN006 180/10 mcg . Patients receive study treatment accord one six treatment sequence accord randomization schedule : 1 . A-B-C , 2 . B-A-C , 3 . C-A-B , 4 . C-B-A , 5 . A-C-B , 6 . B-C-A . The efficacy endpoint - The change Forced Expiratory Volume 1 second ( FEV1 ) within 6 hour . - The change Peak Expiratory Flow Rate ( PEFR ) within 6 hour . - The change Force Vital Capacity ( FVC ) within 6 hour .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Procaterol</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Male female patient age &gt; = 16 year old History FEV1 &gt; =12 % 200 ml increase inhalation shortacting beta 2agonist ; Prebronchodilator FEV1 &gt; 60 % &lt; 90 % predict normal value enrollment ; Ability inhale correctly MDI inhaler Written inform consent obtain . Diagnosis mild moderate persistent asthma accord GINA document history least 6 month duration . Mild Persistent : 1 . Symptoms week less day 2 . Nocturnal symptom twice month 3 . Exacerbations may affect activity sleep 4 . FEV1 PEF &gt; = 80 % predict 5 . PEF FEV1 variability &lt; 20 30 % Moderate Persistent : 1 . Symptoms daily 2 . Nocturnal symptom week 3 . Exacerbations may affect activity sleep 4 . Daily use inhale shortacting beta2agonist 5 . FEV1 PEF &gt; 60 % &lt; 80 % predict 6 . PEF FEV1 variability &gt; 30 % Currently uncontrolled asthma accord GINA guideline ; Allergy , sensitivity intolerance study drug and/or study drug formulation ingredient ; Inability carry pulmonary function test ; Severe asthma associate reduced lung function ; Clinically significant unstable concurrent disease : uncontrolled hyperthyroidism , significant hepatic impairment , poorly control pulmonary disease ( tuberculosis , active mycotic infection lung ) , gastrointestinal ( e.g. , active peptic ulcer ) , neurological haematological autoimmune disease ; Abnormal ECG enrollment ; History nearfatal asthma and/or admission intensive care unit asthma ; History current evidence heart failure , coronary artery disease , myocardial infarction , severe hypertension , cardiac arrhythmia ; Percutaneous transluminal coronary angioplasty ( PTCA ) coronary artery bypass graft ( CABG ) previous 6 month enrollment ; Hospitalization asthma past 3 month enrollment ; Evidence severe asthma exacerbation symptomatic infection airways previous 3 month enrollment ; Current smoker recent ( less one year ) exsmokers , define smoke least 10 pack/years ; History alcohol drug abuse ; Pregnant lactate female able exclude pregnancy study period ; Patients unlikely comply protocol unable understand nature , scope possible consequence study ; Patients receive investigational new drug within last 3 month enrollment ; Patients previously enrol study .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>